SHAHZAD HASHMI: Open Payments
NPI 1770566341 · GAINESVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,974 in 508 payments from 21 companies in 2025. Trend: 2023 $21,708 · 2024 $12,845 · 2025 $8,974
Food & beverage: $8,870Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 76 | $1,169 |
| Otsuka America Pharmaceutical, Inc. | 60 | $1,110 |
| E.R. Squibb & Sons, L.L.C. | 32 | $897 |
| ABBVIE INC. | 35 | $725 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 42 | $717 |
| Neurocrine BioSciences, Inc. | 46 | $654 |
| Alkermes, Inc. | 33 | $651 |
| Supernus Pharmaceuticals, Inc. | 46 | $561 |
| Bausch Health US, LLC | 24 | $497 |
| Vanda Pharmaceuticals Inc. | 26 | $483 |
Products named: COBENFY, VRAYLAR, CAPLYTA, REXULTI, INGREZZA, ABILIFY ASIMTUFII, AUSTEDO XR, Qelbree.
Industry payments across GA — which companies pay providers there.
